
A treatment for diabetic
macular edema (DME)


This site is for US audiences only
INDICATIONS
IMPORTANT SAFETY INFORMATION
IMPORTANT SAFETY INFORMATION
COLLAPSE
EXPAND
BEOVU® (brolucizumab-dbll) injection is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).
You should not use BEOVU if you have an infection in or around the eye, eye inflammation, or if you are allergic to brolucizumab or any of the ingredients in BEOVU.
BEOVU is a prescription medicine given by injection into the eye. Injections in the eye, including BEOVU, may cause an infection of the eye or retinal detachment (separation of retina from the back of the eye). It is important to contact your doctor right away if your eye becomes red, sensitive to light, painful, or you develop any change in your vision.
Increased eye pressure has been seen within 30 minutes of an eye injection, including BEOVU. Sustained increases in eye pressure also have been reported. Your doctor should monitor for this when you receive a BEOVU injection.
There is a potential risk of stroke, heart attack, or blood clots in patients receiving eye injections of vascular endothelial growth factor (VEGF) inhibitor drugs, including BEOVU. Sudden vision loss due to blockage of the blood vessels in the back of the eye and inflammation of blood vessels in the back of the eye have been reported.
The most common side effects reported in patients receiving BEOVU in the wet AMD studies were reduced clarity in vision, cataract, broken blood vessels in the eye, eye pain, and vitreous floaters (moving spots in the field of vision). The most common side effect reported in patients receiving BEOVU in the DME studies was broken blood vessels in the eye.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.
Please see full Prescribing Information.
INDICATIONS
BEOVU® (brolucizumab-dbll) injection is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).